ASP Isotopes Invests $10M in Biotech Firm Opeongo, Securing Strategic Medical Isotope Supply Rights
ASPI sits 76% above its 52-week low of $3.65.
Summary
ASP Isotopes Inc. invested $10 million in biotech company Opeongo, Inc., gaining a strategic stake, board representation, and a right of first offer for medical isotope supply.
Key Events · M&A and Partnerships · ASPI
-
Strategic Investment in Opeongo, Inc.
ASP Isotopes Inc. invested $10 million to acquire 4,356,918 shares of Series Seed-1 Preferred Stock in Opeongo, Inc., a biotechnology company focused on therapeutics.
-
Secured Strategic Investor Rights
The investment grants ASP Isotopes significant investor rights, including the ability to elect one director to Opeongo's board and veto power over certain major corporate actions.
-
Potential Medical Isotope Supply Agreement
ASP Isotopes and Opeongo are obligated to negotiate a supply agreement providing ASP Isotopes with a right of first offer for medical isotopes for Opeongo's pharmaceutical products.
-
Related Party Involvement Noted
ASP Isotopes' CEO, Paul Mann, and Director, Todd Wider, are also involved with Opeongo, with specific voting agreements in place to manage potential conflicts.
Analysis · ASPI · Industrial Applications And Services
ASP Isotopes Inc. has made a significant strategic investment of $10 million in Opeongo, Inc., a biotechnology company developing novel therapeutics. This investment, representing over 1% of ASP Isotopes' market capitalization, grants the company substantial investor rights, including a board seat and veto power over key corporate actions at Opeongo. Crucially, the agreement includes a commitment to negotiate a supply agreement for medical isotopes, aligning with ASP Isotopes' core business and potentially creating a new revenue stream within the pharmaceutical sector. This move diversifies ASP Isotopes' strategic interests and leverages its expertise in isotope supply, following its recent acquisition of Renergen Limited.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.8% of the 1618 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASPI was trading at $6.44 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $793.2M. The 52-week trading range was $3.65 to $14.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.